Javascript must be enabled to continue!
Transsynaptic inhibition of spinal transmission by A2 botulinum toxin
View through CrossRef
Key points
Botulinum toxin A (BoNT/A) blocks synaptic transmission via the cleavage of SNAP‐25. Axonal transport of BoNT/A (A1 type botulinum toxin (A1LL) and A2 type botulinum toxin (A2NTX)) from periphery to the CNS has been described in trigeminal nerve and foreleg muscles.
A1LL and A2NTX were injected into the ipsilateral soleus, and their effects on ipsilateral and contralateral contractions were compared as a measure of local and systemic/transport‐mediated effects. Spinal transmission was also measured to determine axonal and transsynaptic transport of neurotoxin.
A2NTX induced faster and stronger muscle relaxation than A1LL. A1LL arrived at the contralateral muscle by almost equal transport via neural pathways and by the circulation.
A2NTX was mainly transported to contralateral muscles via the blood.
A1LL and A2NTX were carried from peripheral to CNS and vice versa by dual antero‐ and retrograde axonal transport through either motor or sensory neurons.
Our results may point to greater potential safety in A2NTX form.
Abstract Type A botulinum toxin blocks not only ACh release from motor nerve terminals but also central synaptic transmission, including glutamate, noradrenaline, dopamine, ATP, GABA and glycine. Neurotoxins (NTXs) are transported by both antero‐ and retrogradely along either motor or sensory axons for bidirectional delivery between peripheral tissues or the CNS. A newly developed type A2 NTX (A2NTX) injected into one rat foreleg muscle was transported to the contralateral muscle. This finding was consistent with the NTX traveling retrogradely via spinal neurons and then transsynaptically through motor neurons to the contralateral motor neurons within the spinal cord and on to the soleus muscle. In the present study we found that toxin injection into the rat left soleus muscle clearly induced bilateral muscle relaxation in a dose‐dependent fashion, although the contralateral muscle relaxation followed the complete inhibition of toxin‐injected ipsilateral muscles. The toxin‐injected ipsilateral muscle relaxation was faster and stronger in A2NTX‐treated rats than A1LL (BOTOX). A1LL was transported almost equally to the contralateral muscle via neural pathways and the bloodstream. In contrast, A2NTX was mainly transported to contralateral muscles via the blood. A1LL was more successfully transported to contralateral spinal neurons than A2NTX. We also demonstrated that A1LL and A2NTX were carried from peripheral to CNS and vice versa by dual antero‐ and retrograde axonal transport through either motor or sensory neurons.
Title: Transsynaptic inhibition of spinal transmission by A2 botulinum toxin
Description:
Key points
Botulinum toxin A (BoNT/A) blocks synaptic transmission via the cleavage of SNAP‐25.
Axonal transport of BoNT/A (A1 type botulinum toxin (A1LL) and A2 type botulinum toxin (A2NTX)) from periphery to the CNS has been described in trigeminal nerve and foreleg muscles.
A1LL and A2NTX were injected into the ipsilateral soleus, and their effects on ipsilateral and contralateral contractions were compared as a measure of local and systemic/transport‐mediated effects.
Spinal transmission was also measured to determine axonal and transsynaptic transport of neurotoxin.
A2NTX induced faster and stronger muscle relaxation than A1LL.
A1LL arrived at the contralateral muscle by almost equal transport via neural pathways and by the circulation.
A2NTX was mainly transported to contralateral muscles via the blood.
A1LL and A2NTX were carried from peripheral to CNS and vice versa by dual antero‐ and retrograde axonal transport through either motor or sensory neurons.
Our results may point to greater potential safety in A2NTX form.
Abstract Type A botulinum toxin blocks not only ACh release from motor nerve terminals but also central synaptic transmission, including glutamate, noradrenaline, dopamine, ATP, GABA and glycine.
Neurotoxins (NTXs) are transported by both antero‐ and retrogradely along either motor or sensory axons for bidirectional delivery between peripheral tissues or the CNS.
A newly developed type A2 NTX (A2NTX) injected into one rat foreleg muscle was transported to the contralateral muscle.
This finding was consistent with the NTX traveling retrogradely via spinal neurons and then transsynaptically through motor neurons to the contralateral motor neurons within the spinal cord and on to the soleus muscle.
In the present study we found that toxin injection into the rat left soleus muscle clearly induced bilateral muscle relaxation in a dose‐dependent fashion, although the contralateral muscle relaxation followed the complete inhibition of toxin‐injected ipsilateral muscles.
The toxin‐injected ipsilateral muscle relaxation was faster and stronger in A2NTX‐treated rats than A1LL (BOTOX).
A1LL was transported almost equally to the contralateral muscle via neural pathways and the bloodstream.
In contrast, A2NTX was mainly transported to contralateral muscles via the blood.
A1LL was more successfully transported to contralateral spinal neurons than A2NTX.
We also demonstrated that A1LL and A2NTX were carried from peripheral to CNS and vice versa by dual antero‐ and retrograde axonal transport through either motor or sensory neurons.
Related Results
Antiarrhythmic properties of Botulinum toxin A: in vitro studies on human and rat cardiomyocytes
Antiarrhythmic properties of Botulinum toxin A: in vitro studies on human and rat cardiomyocytes
Abstract
Botulinum toxin A is a well-known neurotransmitter inhibitor with a wide range of applications in modern medicine. In recent years, botulinum toxin preparations ha...
Role of botulinum toxin in hand and upper limb disorders relevant to hand therapy
Role of botulinum toxin in hand and upper limb disorders relevant to hand therapy
Introduction This article reviews the mechanism of action of botulinum toxin and provides an overview of its use in hand disorders relevant to hand therapy such as hyperhidrosis, s...
Public perception and knowledge toward the non-cosmetic use of botulinum toxin in dermatology practices
Public perception and knowledge toward the non-cosmetic use of botulinum toxin in dermatology practices
Background: While botulinum toxin is widely known for its cosmetic applications, its therapeutic potential in dermatology remains under-recognized by the general public. This study...
Botulinum toxin A and chronic back pain: a randomized, double‐blinded study. (Walter Reed Army Medical Center, Washington, DC) Neurology. 2001;56:1290–1293.
Botulinum toxin A and chronic back pain: a randomized, double‐blinded study. (Walter Reed Army Medical Center, Washington, DC) Neurology. 2001;56:1290–1293.
This study investigated the efficacy of botulinum toxin A in chronic low back pain and associated disabilities. Thirty‐one consecutive patients with chronic low back pain who met t...
The entry of diphtheria toxin into the mammalian cell cytoplasm: evidence for lysosomal involvement.
The entry of diphtheria toxin into the mammalian cell cytoplasm: evidence for lysosomal involvement.
Lysosomotropic amines, such as ammonium chloride, are known to protect cells from the cytotoxic effects of diphtheria toxin. These drugs are believed to inhibit the transport of th...
Outcome of delayed versus immediate casting on spasticity of lower limb muscles in cerebral palsy post-botulinum toxin injection
Outcome of delayed versus immediate casting on spasticity of lower limb muscles in cerebral palsy post-botulinum toxin injection
Background: Botulinum toxin type A (BTX-A) is widely used to treat spasticity in children. The optimal strategy for the combined treatment of casting and BTX-A injections is not kn...
Facing depression with botulinum toxin: Literature review
Facing depression with botulinum toxin: Literature review
IntroductionAffecting over 120 million people, major depressive disorder (MDD) is characterized by low mood, lack of interest and a cluster of other vegetative and cognitive sympto...
Oxymetazoline hydrochloride ophthalmic solution, 0.1%, boosts the effects of botulinum toxin on blepharospasm: a case series
Oxymetazoline hydrochloride ophthalmic solution, 0.1%, boosts the effects of botulinum toxin on blepharospasm: a case series
Abstract
Background
Oxymetazoline hydrochloride ophthalmic solution (0.1%) is a medication used to treat blepharoptosis. Patients who suffer from bl...

